Nektar Therapeutics (NKTR) Operating Margin
- Operating margin · 12 months: Value -257.80%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -257.80% | Operating income / revenue. Period ending 2026-06-30. $-140.73M ÷ $54.59M × 100 ≈ -257.80% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -140.73M USD | Operating Income (Loss) |
| Revenue | 54.59M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | Cost of Goods and Services Sold |
| Research and development | 131.77M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-140.73M | $54.59M | (m) | $131.77M | (m) | -257.80% |
| 2026-03-31 | $-134.62M | $55.63M | (m) | $122.53M | (m) | -241.98% |
| 2025-12-31 | $-140.10M | $55.23M | $0.00 | $117.33M | (m) | -253.66% |
| 2025-09-30 | $-98.09M | $62.60M | $7.98M | $116.36M | (m) | -156.69% |
| 2025-06-30 | $-100.76M | $74.93M | $12.41M | $124.14M | (m) | -134.47% |
| 2025-03-31 | $-114.31M | $87.25M | $22.15M | $123.98M | (m) | -131.01% |
| 2024-12-31 | $-105.20M | $98.43M | $30.69M | $120.91M | (m) | -106.88% |
| 2024-09-30 | $-153.06M | $93.14M | $29.99M | $122.11M | (m) | -164.34% |
| 2024-06-30 | $-163.58M | $93.16M | $37.99M | $111.14M | (m) | -175.59% |
| 2024-03-31 | $-164.40M | $90.17M | $35.24M | $111.10M | (m) | -182.33% |
| 2023-12-31 | $-263.68M | $90.12M | $33.77M | $114.16M | (m) | -292.59% |
| 2023-09-30 | $-282.64M | $88.26M | $32.72M | $118.96M | (m) | -320.24% |
| 2023-06-30 | $-292.08M | $87.74M | $25.26M | $128.48M | (m) | -332.89% |
| 2023-03-31 | $-394.32M | $88.83M | $23.38M | $141.54M | (m) | -443.91% |
| 2022-12-31 | $-376.17M | $92.06M | $21.64M | $218.32M | (m) | -408.63% |
| 2022-09-30 | $-436.61M | $95.04M | $21.57M | $283.20M | (m) | -459.39% |
| 2022-06-30 | $-495.90M | $96.34M | $21.90M | $353.35M | (m) | -514.76% |
| 2022-03-31 | $-453.27M | $103.08M | $24.46M | $411.92M | (m) | -439.72% |
| 2021-12-31 | $-446.10M | $101.91M | $24.90M | $400.27M | (m) | -437.76% |
| 2021-09-30 | $-443.91M | $100.36M | $23.06M | $403.38M | (m) | -442.32% |
| 2021-06-30 | $-433.37M | $105.47M | $23.32M | $400.17M | (m) | -410.88% |
| 2021-03-31 | $-400.87M | $125.99M | $21.42M | $395.30M | (m) | -318.18% |
| 2020-12-31 | $-425.11M | $152.91M | $19.48M | $408.68M | (m) | -278.00% |
| 2020-09-30 | $-424.03M | $163.31M | $21.14M | $416.32M | (m) | -259.64% |
| 2020-06-30 | $-419.72M | $162.50M | $20.50M | $414.84M | (m) | -258.29% |
| 2020-03-31 | $-452.98M | $136.97M | $19.75M | $425.09M | (m) | -330.72% |
| 2019-12-31 | $-440.04M | $114.62M | $21.37M | $434.57M | (m) | -383.92% |
| 2019-09-30 | $-430.69M | $120.58M | $22.85M | $433.08M | (m) | -357.18% |
| 2019-06-30 | $-430.59M | $119.13M | $22.70M | $436.93M | (m) | -361.46% |
| 2019-03-31 | $653.98M | $1.18B | $23.21M | $418.57M | (m) | 55.26% |
| 2018-12-31 | $687.93M | $1.19B | $24.41M | $399.54M | (m) | 57.65% |
| 2018-09-30 | $764.19M | $1.25B | (m) | $372.08M | (m) | 61.19% |
| 2018-06-30 | $932.31M | $1.37B | (m) | $334.90M | (m) | 67.85% |
| 2018-03-31 | $-91.94M | $321.00M | (m) | $306.83M | (m) | -28.64% |
| 2017-12-31 | $-59.64M | $307.71M | (m) | $268.46M | (m) | -19.38% |
| 2017-09-30 | $-67.75M | $249.70M | (m) | $237.26M | (m) | -27.13% |
| 2017-06-30 | $-170.14M | $133.10M | (m) | $223.50M | (m) | -127.82% |
| 2017-03-31 | $-157.81M | $131.28M | (m) | $215.59M | (m) | -120.21% |
| 2016-12-31 | $-112.86M | $165.44M | (m) | $203.80M | (m) | -68.22% |
| 2016-09-30 | $-110.08M | $167.35M | (m) | $200.70M | (m) | -65.77% |
| 2016-06-30 | $-76.75M | $190.97M | (m) | $191.98M | (m) | -40.19% |
| 2016-03-31 | $-81.90M | $180.87M | (m) | $185.04M | (m) | -45.28% |
| 2015-12-31 | $-29.37M | $230.78M | (m) | $182.79M | (m) | -12.73% |
| 2015-09-30 | $-37.49M | $210.97M | (m) | $174.15M | (m) | -17.77% |
| 2015-06-30 | $42.41M | $283.88M | (m) | $165.12M | (m) | 14.94% |
| 2015-03-31 | $62.96M | $289.74M | (m) | $156.41M | (m) | 21.73% |
| 2014-12-31 | $-16.48M | $200.71M | (m) | $147.73M | (m) | -8.21% |
| 2014-09-30 | $-14.89M | $212.30M | (m) | $157.49M | (m) | -7.01% |
| 2014-06-30 | $-101.74M | $140.34M | (m) | $167.20M | (m) | -72.49% |
| 2014-03-31 | $-111.43M | $145.69M | (m) | $182.73M | (m) | -76.48% |
| 2013-12-31 | $-120.13M | $148.92M | (m) | $190.01M | (m) | -80.67% |
| 2013-09-30 | $-127.62M | $138.92M | (m) | $188.13M | (m) | -91.86% |
| 2013-06-30 | $-153.99M | $96.42M | (m) | $178.24M | (m) | -159.70% |
| 2013-03-31 | $-148.67M | $86.25M | (m) | $159.21M | (m) | -172.38% |
| 2012-12-31 | $-141.20M | $81.19M | (m) | $148.68M | (m) | -173.91% |
| 2012-09-30 | $-132.29M | $75.83M | (m) | $135.60M | (m) | -174.46% |
| 2012-06-30 | $-120.73M | $84.48M | (m) | $132.61M | (m) | -142.90% |
| 2012-03-31 | $-128.00M | $78.13M | (m) | $131.68M | (m) | -163.83% |
| 2011-12-31 | $-123.94M | $71.48M | (m) | $126.77M | (m) | -173.39% |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $-28.25M | $159.04M | (m) | $108.06M | (m) | -17.77% |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $-95.13M | $71.93M | (m) | $95.11M | (m) | -132.25% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |